⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Calluna Pharma and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Calluna Pharma
↗Oslo, Norway
Calluna Pharma is a clinical-stage biotechnology company focused on developing novel therapies for inflammatory and fibrotic diseases. The company leverages the body's innate immune system by targeting upstream innate immune amplifiers, such as DAMPs (Damage-Associated Molecular Patterns), to disrupt downstream signaling pathways associated with chronic inflammation and fibrosis.
Formed in 2023 through the merger of Oxitope Pharma and Arxx Therapeutics, Calluna Pharma is backed by venture capital and is currently advancing a pipeline of selective monoclonal antibodies. Its lead candidate, CAL101, is in Phase 2 clinical development for idiopathic pulmonary fibrosis (IPF).
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Inflammatory and Fibrotic Diseases
SIZE & FINANCIALS
Employees:1-50
Founded:2023
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$82M
Investors:Forbion, Sarsia, p53, Investinor
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Monoclonal antibody (mAb)
Active Trials:1
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Arxx Therapeutics
Key Partnerships:Lilly ExploR&D™ (partnership for CAL101)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Mark Gaffney - CEO
Margrethe Sørgaard - SVP Clinical Operations and Pharmacovigilance
Board Members:Mark Altmeyer (Independent Chair), Gijs van den Brink
LINKS
Website:callunapharma.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Calluna Pharma. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.